RECOVERY Trial
The Randomised Evaluation of COVID-19 Therapy (RECOVERY Trial)[1] is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection.[2][3][4] The trial was later expanded to Indonesia, Nepal and Vietnam.[5] The trial has tested ten interventions on adults: eight repurposed drugs, one newly developed drug and convalescent plasma.[2]
Not to be confused with RECOVER Initiative.
As of 25 June 2021, the following treatments are allocated at random to hospitalized people with severe COVID-19 infection:[2]
Children with PIMS-TS may also be allocated the following:[10]
The following treatments have previously been included in the trial and obtained positive results:
The following treatments have previously been included in the trial and were closed to new entrants after being shown to be ineffective.[11][12][13][14]:
Operations[edit]
The trial is run by the Nuffield Departments of Population Health and of Medicine at the University of Oxford[12][9] and supported by the National Institute for Health Research (NIHR). The study is led by Peter Horby and Martin Landray who serve as Co-Chief Investigators of the trial.[15][16] By July 2020, the trial was in progress at 176 NHS hospitals in the UK, involving many thousands of health professionals.[17]
The trial began in March 2020. As of March 2021 the trial had enrolled more than 40,000 COVID-19 participants admitted to hospitals in the UK;[7] the estimated primary completion date was December 2021, and the estimated study completion date was December 2031.[6][13]
